Revised View Enhances Provenge OS Data
A further analysis of clinical trial data for sipuleucel-T (Provenge) suggests that it may have delivered a greater overall survival benefit than previously described.
Investors Eye ASCO Abstracts for Potential Winners
While oncology specialists await the latest research news from the upcoming ASCO annual meeting next month, so do legions of biopharma investors. Here's a look at companies presenting pivotol trial data at this year's conference.
2 Clarke Drive Cranbury, NJ 08512